Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1654 1675 1683
This examiner grants 56% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19310993 | SEMAGLUTIDE FOR USE IN MEDICINE | Final Rejection | Novo Nordisk A/S |
| 18163773 | TRI-PEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISORDERS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 17266897 | TRI-PEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISORDERS | Final Rejection | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 19329417 | CELL-PENETRATING PEPTIDE COMPOUNDS | Non-Final OA | Ohio State Innovation Foundation |
| 18755185 | CELL-PENETRATING PEPTIDE SEQUENCES | Non-Final OA | Ohio State Innovation Foundation |
| 17760381 | NANOPARTICLES ENCAPSULATING SMALL MOLECULES | Non-Final OA | ETH ZURICH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy